With no or relatively less impact on HSCs, targeting METTL14, ALKBH5, or YTHDF2 is promising for eradicating LSCs and reducing relapse and chemoresistance in AML patients. This evidence concerns the gene YTHDF2 and acute myeloid leukemia.